Abstract
Heparin and heparin-like oligo- and polysaccharides bind to fibroblast growth factors (FGFs) and modulate their ability to form active ternary complexes with FGF receptors (FGFRs). Considerable efforts have been made in recent years to identify the minimal heparin and heparan sulfate (HS) sequences that bind and activate individual FGFs. Heparin sequences involved in interaction with FGFs invariably contain at least one residue of 2-O-sulfated iduronic acid (IdoA2S), which adopts either the 1C4 chair conformation or the equienergetic skew-boat 2S0. In solution and in the absence of a binding protein, both these conformations are present in a dynamic equilibrium. In oligosaccharide-protein co-crystals, the protein selects those conformers that provide optimal contacts. The crystalline structure of a heparin hexasaccharide/FGF complex exhibits one of the two IdoA2S residues in the active site of the growth factor in 1C4 conformation and the other (outside the active site) in 2S0 conformation. NMR studies suggest that active conformations of heparin/HS oligosaccharides in solution could be distinct from those adopted in crystals. Heparin tetrasaccharides in the presence of FGF1 and FGF2 have both their IdoA2S residues prevalently in the 1C4 form. Current NMR and molecular modelling studies are being extended to longer heparin oligosaccharides as well as to heparins with “glycol-split” residues along their chains.
Keywords: heparin, FGF, oligosaccharide conformation, protein-carbohydrate interaction, NMR spectroscopy
Current Pharmaceutical Design
Title: Interaction of Heparins with Fibroblast Growth Factors: Conformational Aspects
Volume: 13 Issue: 20
Author(s): Marco Guerrini, Milos HricovIni and Giangiacomo Torri
Affiliation:
Keywords: heparin, FGF, oligosaccharide conformation, protein-carbohydrate interaction, NMR spectroscopy
Abstract: Heparin and heparin-like oligo- and polysaccharides bind to fibroblast growth factors (FGFs) and modulate their ability to form active ternary complexes with FGF receptors (FGFRs). Considerable efforts have been made in recent years to identify the minimal heparin and heparan sulfate (HS) sequences that bind and activate individual FGFs. Heparin sequences involved in interaction with FGFs invariably contain at least one residue of 2-O-sulfated iduronic acid (IdoA2S), which adopts either the 1C4 chair conformation or the equienergetic skew-boat 2S0. In solution and in the absence of a binding protein, both these conformations are present in a dynamic equilibrium. In oligosaccharide-protein co-crystals, the protein selects those conformers that provide optimal contacts. The crystalline structure of a heparin hexasaccharide/FGF complex exhibits one of the two IdoA2S residues in the active site of the growth factor in 1C4 conformation and the other (outside the active site) in 2S0 conformation. NMR studies suggest that active conformations of heparin/HS oligosaccharides in solution could be distinct from those adopted in crystals. Heparin tetrasaccharides in the presence of FGF1 and FGF2 have both their IdoA2S residues prevalently in the 1C4 form. Current NMR and molecular modelling studies are being extended to longer heparin oligosaccharides as well as to heparins with “glycol-split” residues along their chains.
Export Options
About this article
Cite this article as:
Marco Guerrini , Milos HricovIni and Giangiacomo Torri , Interaction of Heparins with Fibroblast Growth Factors: Conformational Aspects, Current Pharmaceutical Design 2007; 13 (20) . https://dx.doi.org/10.2174/138161207781039733
DOI https://dx.doi.org/10.2174/138161207781039733 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements